FM - Artigos publicados em periódicos
URI Permanente para esta coleção
Navegar
Navegando FM - Artigos publicados em periódicos por Autor "Albuquerque, Denilson Campos de"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
Item Atualização da Diretriz Brasileira de Insuficiência Cardíaca Crônica - 2012(2012) Bocchi, Edimar Alcides; Braga, Fabiana Goulart Marcondes; Bacal, Fernando; Ferraz, Almir Sérgio; Albuquerque, Denilson Campos de; Almeida, Dirceu Rodrigues de; Mesquita, Evandro Tinoco; Pinto, Fábio Vilas-Boas; Cruz, Fátima das Dores da; Ramires, Felix José Alvarez; Rassi, SalvadorItem I Diretriz Latino-Americana para Avaliação e Conduta na Insuficiência Cardíaca Descompensada(2005) Bocchi, Edimar Alcides; Pinto, Fábio Vilas-Boas; Perrone, Sergio; Caamaño, Angel G.; Clausell, Nadine Oliveira; Moreira, Maria da Consolação Vieira; Thierer, Jorge; Grancelli, Hugo Omar; Serrano Junior, Carlos Vicente; Albuquerque, Denilson Campos de; Almeida, Dirceu Rodrigues de; Rassi, SalvadorItem Levosimendana em pacientes com insuficiência cardíaca descompensada: eficácia em uma coorte brasileira. Resultados do estudo BELIEF(2008) Bocchi, Edimar Alcides; Pinto, Fábio Vilas-Boas; Moreira, Maria da Consolação Vieira; Pereira-Barretto, Antonio Carlos; Lage, Silvia Helena Gelás; Albuquerque, Denilson Campos de; Baima, Jader; Rassi, Salvador; Ribeiro, Jorge PintoBackground: Levosimendan is a new inodilatory agent that enhances cardiac contractility via Ca(2+) sensitization and induces vasodilation through the activation of KATP/BKCa. Objective: To study the efficacy and safety of levosimendan in a decompensated heart failure (DHF) Brazilian cohort, and in β-adrenergic agonist resistant patients. Methods: The Brazilian Evaluation of Levosimendan Infusion Efficacy (BELIEF) study was prospective, multicenter, observational and included 182 high-risk DHF patients, all of which received open-label levosimendan. Primary end point was hospital discharge without additional inotropic therapy (responder). Secondary end points were changes in hemodynamics, clinical parameters, and brain natriuretic peptide (BNP). Results: Mortality rate was 14.8%, and 139 of 182 patients were responders. In non responders it was 62.8%. Systolic blood pressure was a predictor of response. In β-adrenergic agonist resistant group, 55.8% were responders. Overall, 54 patients experienced at least one adverse event; most of them resolved either spontaneously or after levosimendan dose reduction. A significant improvement in quality of life was verified at 2-6 months of follow-up (p<0.0001). Conclusion: Our results suggest levosimendan infusion as an alternative therapy in the short term management of DHF patients. HF severity can influence the response to levosimendan treatment. Prospective studies are warranted in a Brazilian cohort including Chagas heart disease.Item Rationale and design - breathe registry- I brazilian registry of heart failure(2013) Rohde, Luis Eduardo Paim; Danzmann, Luiz Claudio; Canesin, Manoel Fernandes; Hoffmann Filho, Conrado Roberto; Fragata Filho, Abilio Augusto; Baruzzi, Antonio Claudio do Amaral; Pereira-Barretto, Antonio Carlos; Matsubara, Beatriz Bojikian; Mady, Charles; Albuquerque, Denilson Campos de; Rassi, SalvadorBackground: Several local registries have sought to individually depict clinical characteristics of patients hospitalized with heart failure (HF) in Brazilian hospitals and communities. Overall, the analysis of these data suggests that there are important differences in etiology, decompensation factors, treatment and prognosis of patients with HF in different Brazilian regions. Objectives: To evaluate the demographic, clinical and prognostic characteristics of 1,200 patients admitted with a clinical diagnosis of decompensated HF in a group of 60 hospitals representative of the different Brazilian regions. Methods: Transversal observational study (registry) with a longitudinal twelve-month follow-up (admission consultations, hospital discharge, three months, six months and twelve months after inclusion), in which patients admitted to public and private hospitals clinical with a primarily defined HF diagnosis will be studied. Results: The results will be shown soon after data collection completion, quality assessment and statistical analysis. Conclusions: The results of this multicenter registry will allow for a more appropriate planning of financial, technological and personal resource supply for the health care area, as well as the planning of more effective preventive measures in decompensated HF